REGULATORY

• MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
  October 16, 2023

• Japan’s New Economic Package to Include Dementia Measures: PM
  October 16, 2023

• Xarelto’s Label Expansion Up for Japan Panel Review on Oct. 27
  October 16, 2023

• MHLW to Swiftly Deliberate Additional Purchase of COVID Jabs: Minister
  October 16, 2023

• Label Revisions Ordered for G-CSF Agents, Yervoy and More
  October 13, 2023

• MHLW Preparatory Council Boots Up for Japan-Version of CDC
  October 13, 2023

• MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
  October 12, 2023

• Drug Innovation Measures Likely to Be Embraced in Govt Economic Package
  October 12, 2023

• Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
  October 12, 2023

• MHLW Pondering Every Possible Avenue to Supply Cough Drugs: Minister
  October 11, 2023

• MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
  October 11, 2023

• Japan Panel to Review Label Expansions for Opdivo, Adcetris, and More on Oct. 23
  October 10, 2023

• Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
  October 5, 2023

• Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
  October 5, 2023

• WHO Recommends Takeda’s Dengue Vaccine in Children Ages 6-16
  October 4, 2023

• MHLW Set to Wrap Up Drug Copay Debate by Year-End: Minister
  October 4, 2023

• NHO Data Now Available through PMDA’s MID-NET Database
  October 3, 2023

• As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
  October 2, 2023

• Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
  October 2, 2023

• MHLW Proposes Setting Key Drugs as Category Separated from Bundled Trades
  September 29, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• …
• Next ›
• 最終 »